CVS unveiled Cordavis, a new subsidiary focused on biosimilars in the U.S., on Aug. 23.

Two medications, ephedrine sulfate and hydroxychloroquine sulfate, were denied inclusion on the FDA's 503B bulks list, the agency said Aug. 21. 

The FDA warned Amazon, Walmart and two other companies for selling products for molluscum contagiosum — a viral skin infection that does not have any approved over-the-counter treatments. 

The American Hospital Association stated its opposition to a drafted July 28 proposal from the U.S. House Energy and Commerce Committee that could lead to limit access to the 340B Drug Pricing Program in an Aug. 22 letter. 

More than 97 percent of health systems and hospitals said the shortage of carboplatin, a bladder cancer drug, is affecting pharmacy operations and patient care, according to a survey conducted by Vizient. 

The FDA on Aug. 21 approved Pfizer's maternal vaccine meant to protect infants from respiratory syncytial virus. 

The Joint Commission has updated medication compounding requirements for hospitals to better align with national practice standards, the organization said Aug. 21. 

The World Health Organization's list of essential medications now includes a heart polypill after a study led by a Mount Sinai researcher found the drug reduced cardiovascular mortality by 33 percent. 

Type 2 diabetes drug Ozempic and weight loss medication Wegovy cost hundreds of dollars more in the U.S. than similar nations, and Novo Nordisk is profiting so much that Denmark's economy is shifting. 

The FDA placed a partial clinical hold on Gilead Science's phase 3 study of a potential therapy for acute myeloid leukemia, the Foster City, Calif.-based biopharmaceutical company said Aug. 21.